Behavioral evidence for supersensitivity after chronic administration of haloperidol, clozapine, and thioridazine
References (19)
- et al.
Neuropharmacology
(1974) - et al.
Eur. J. Pharmacol.
(1973) - et al.
Brain Research
(1971) - et al.
Eur. J. Pharmacol.
(1975) - et al.
Psychopharm. Comm.
(1975) - et al.
- et al.
Life Sci.
(1973) - et al.
- et al.
Arch. Gen. Psychiat.
(1972)
Cited by (95)
Rationale and neurobiological effects of treatment with antipsychotics in patients with chronic schizophrenia considering dopamine supersensitivity
2021, Behavioural Brain ResearchCitation Excerpt :A study reported that clozapine, like aripiprazole, did not cause DRD2 up-regulation at cell levels [154]. On the other hand, several animal models showed behavioral supersensitivity caused by clozapine [155,156]. Past studies have shown that clozapine greatly improved tardive dyskinesia which was caused by previous medications [157].
Continuous versus extended antipsychotic dosing in schizophrenia: Less is more
2021, Behavioural Brain ResearchCitation Excerpt :This exaggerated response is the most commonly used index of antipsychotic-induced dopamine supersensitivity in laboratory rodents. In rats, antipsychotic-induced dopamine supersensitivity produces robust sensitization to the psychomotor-activating effects of dopamine agonists, but also to their reward-enhancing effects [39,40,43–49]. Antipsychotic-evoked dopamine supersensitivity is often studied in otherwise neurologically intact animals, but it can also be seen in well-established animal models of schizophrenia symptoms [45].
5-HT<inf>2</inf> receptors modulate the expression of antipsychotic-induced dopamine supersensitivity
2015, European NeuropsychopharmacologyCitation Excerpt :However, amphetamine-induced locomotion permits an accessible and rapid assessment of dopamine function following antipsychotic treatment. In parallel, other studies have shown that antipsychotic-induced dopamine supersensitivity is also characterized by an enhanced ability of the direct dopamine receptor agonist apomorphine to stimulate both horizontal locomotor activity and stereotyped behaviour (Asper et al., 1973; Clow et al., 1979; Gianutsos et al., 1974; Montanaro et al., 1982; Sayers et al., 1975; Smith and Davis, 1975, 1976). Finally, a question raised by our findings is whether treatment with an atypical antipsychotic would induce similar alterations in 5-HT2 receptor density and function.
Antipsychotic treatment leading to dopamine supersensitivity persistently alters nucleus accumbens function
2015, NeuropharmacologyCitation Excerpt :For instance, antipsychotic-induced dopamine supersensitivity is thought to increase the incidence of both psychosis upon treatment cessation (Chouinard et al., 1978; Tollefson et al., 1999) and movement disorders (Casey, 1995). In addition, it increases the ability of dopamine agonists to potentiate both psychomotor activity (Asper et al., 1973; Samaha et al., 2008, 2007; Smith and Davis, 1976) and operant responding for conditioned reward (CR; (Bedard et al., 2011, 2013). Finally, in animal models of antipsychotic-like effects, dopamine supersensitivity following antipsychotic treatment is linked to decreased efficacy of currently used (Samaha et al., 2008, 2007) and experimental (Gill et al., 2014) antipsychotic compounds.
Parallels between behavioral and neurochemical variability in the rat vacuous chewing movement model of tardive dyskinesia
2012, Behavioural Brain ResearchT-type calcium channel antagonism produces antipsychotic-like effects and reduces stimulant-induced glutamate release in the nucleus accumbens of rats
2012, NeuropharmacologyCitation Excerpt :Also, pre-treatment with TTA-A2 did not sensitize animals to the psychomotor activating effects of amphetamine, in contrast with what was observed with haloperidol. This is potentially important because it has been hypothesized that the sensitized stimulant response produced by chronic treatment with antipsychotics (Rebec et al., 1982; Samaha et al., 2007; Smith and Davis, 1975, 1976) might reflect neurobiological changes associated with a loss of clinical efficacy (Samaha et al., 2007). Third, TTA-A2 decreased the ability of amphetamine to engage the nucleus accumbens (but not caudate putamen), as revealed by a decrease in amphetamine-induced c-fos expression in this region.